Akebia Therapeutics (AKBA) announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion recommending the European Commission to approve XOANACYL for the treatment of concomitant elevated serum phosphorous and iron deficiency in adult patients with chronic kidney disease. The EC will review the recommendation, and a final decision is expected in approximately two months.
Averoa licensed the rights to develop and commercialize ferric citrate from Akebia in the European Economic Area and certain countries in Europe and the Middle East.
For More Such Health News, visit rttnews.com.
For comments and feedback: editorial@rttnews.com